Pseudocapsule thickness is positively associated with prognosis in patients with clear cell renal cell carcinoma.

IF 3.4 2区 医学 Q2 ONCOLOGY BMC Cancer Pub Date : 2025-02-17 DOI:10.1186/s12885-025-13721-z
Wei Xi, Yingyong Hou, Jun Hou, Jianming Guo
{"title":"Pseudocapsule thickness is positively associated with prognosis in patients with clear cell renal cell carcinoma.","authors":"Wei Xi, Yingyong Hou, Jun Hou, Jianming Guo","doi":"10.1186/s12885-025-13721-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tumour pseudocapsule shows plasticity, whose representative indicator- pseudocapsule thickness- was little studied in clear cell renal cell carcinoma (ccRCC).</p><p><strong>Methods: </strong>We enrolled 1037 ccRCC patients who underwent surgery between 2006 and 2013 at our institution. The patients did not receive therapy before surgery and were confirmed to have a pathological pseudocapsule. The associations of pseudocapsule thickness with overall survival and disease-free survival were studied using multivariable Cox regression analyses. Patients were stratified using points of maximum separation. Influential factors were examined with logistic regression.</p><p><strong>Results: </strong>The average thickness was 0.47 mm (median: 0.43, interquartile range: 0.28-0.6). The average follow-up was 92.1. In multivariable analyses, every 0.1-mm increase in thickness resulted in a decreased risk of death (hazard ratio (HR) 0.906, p = 0.011) but not recurrence (HR 0.948, p = 0.105). For patients with a pseudocapsule thickness of 0.2 mm, 0.4 mm, 0.6 mm, 0.8 mm and 1.0 mm, the estimated 10-year overall survival rates were 74.9%, 83.3%, 87.8%, 90.1% and 91.0%, and the 10-year disease-free survival rates were 69.6%, 76.6%, 80.8%, 83.1% and 84.1%, respectively, with the best cut-off value being approximately 0.37 mm. The results of logistic regression revealed that female sex (p < 0.001), age (p = 0.002), a higher neutrophil count (p = 0.011), large tumour size (p < 0.001) and necrosis (p = 0.011) were independently associated with a thin pseudocapsule (≤ 0.37 mm).</p><p><strong>Conclusions: </strong>Pseudocapsule thickness is heterogeneous in clear cell renal cell carcinoma. Generally, increased thickness is associated with improvement in long-term survival. A pseudocapsule being 0.37 mm or thinner is mostly influenced by both systematic and tumor-related parameters.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"279"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834655/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-13721-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Tumour pseudocapsule shows plasticity, whose representative indicator- pseudocapsule thickness- was little studied in clear cell renal cell carcinoma (ccRCC).

Methods: We enrolled 1037 ccRCC patients who underwent surgery between 2006 and 2013 at our institution. The patients did not receive therapy before surgery and were confirmed to have a pathological pseudocapsule. The associations of pseudocapsule thickness with overall survival and disease-free survival were studied using multivariable Cox regression analyses. Patients were stratified using points of maximum separation. Influential factors were examined with logistic regression.

Results: The average thickness was 0.47 mm (median: 0.43, interquartile range: 0.28-0.6). The average follow-up was 92.1. In multivariable analyses, every 0.1-mm increase in thickness resulted in a decreased risk of death (hazard ratio (HR) 0.906, p = 0.011) but not recurrence (HR 0.948, p = 0.105). For patients with a pseudocapsule thickness of 0.2 mm, 0.4 mm, 0.6 mm, 0.8 mm and 1.0 mm, the estimated 10-year overall survival rates were 74.9%, 83.3%, 87.8%, 90.1% and 91.0%, and the 10-year disease-free survival rates were 69.6%, 76.6%, 80.8%, 83.1% and 84.1%, respectively, with the best cut-off value being approximately 0.37 mm. The results of logistic regression revealed that female sex (p < 0.001), age (p = 0.002), a higher neutrophil count (p = 0.011), large tumour size (p < 0.001) and necrosis (p = 0.011) were independently associated with a thin pseudocapsule (≤ 0.37 mm).

Conclusions: Pseudocapsule thickness is heterogeneous in clear cell renal cell carcinoma. Generally, increased thickness is associated with improvement in long-term survival. A pseudocapsule being 0.37 mm or thinner is mostly influenced by both systematic and tumor-related parameters.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
透明细胞肾细胞癌患者假包膜厚度与预后呈正相关。
背景:肿瘤假包膜具有可塑性,其代表性指标假包膜厚度在透明细胞肾细胞癌(ccRCC)中研究较少。方法:我们纳入了2006年至2013年在我院接受手术的1037例ccRCC患者。患者术前未接受治疗,确认为病理性假包膜。采用多变量Cox回归分析研究假包膜厚度与总生存期和无病生存期的关系。采用最大分离点对患者进行分层。采用logistic回归检验影响因素。结果:平均厚度为0.47 mm(中位数为0.43,四分位数间距为0.28 ~ 0.6)。平均随访时间为92.1。在多变量分析中,厚度每增加0.1 mm导致死亡风险降低(风险比(HR) 0.906, p = 0.011),但不会导致复发(HR 0.948, p = 0.105)。假包膜厚度为0.2 mm、0.4 mm、0.6 mm、0.8 mm和1.0 mm的患者,10年总生存率分别为74.9%、83.3%、87.8%、90.1%和91.0%,10年无病生存率分别为69.6%、76.6%、80.8%、83.1%和84.1%,最佳临界值约为0.37 mm。结论:肾透明细胞癌假包膜厚度具有异质性。通常,厚度的增加与长期生存的改善有关。0.37 mm或更薄的假包膜主要受系统和肿瘤相关参数的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BMC Cancer
BMC Cancer 医学-肿瘤学
CiteScore
6.00
自引率
2.60%
发文量
1204
审稿时长
6.8 months
期刊介绍: BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
期刊最新文献
Elevated m6A RNA modifications associate with immune dysregulation and cancer in people with HIV-1. TACE combined with tislelizumab and lenvatinib in the treatment of intermediate-to-advanced hepatocellular carcinoma: a retrospective real-world study. CALLY index provides improved prognostic stratification compared with other inflammation-based scores in glioblastoma treated with the stupp protocol. Diagnostic accuracy of an AI-based pathologic response assessment in locally advanced non-small cell lung cancer after neoadjuvant chemo-immunotherapy. Presenting the Brazilian physical activity during cancer treatment guidelines: adaptations and challenges in a low- and middle-income context.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1